# What to ask about a sore joint *Straight Answers | Regenerative Medicine Surprise* > Regenerative medicine Surprise answers on PRP, daily care, costs, urgent changes, and the closest clinic. This page gives straight answers about joint soreness, home care, blood-based shots, cost, and the nearby clinic. You’ll find each answer below its question. Keep the parts you want to discuss with your doctor. ## Sources 1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to. Caplan AI, et al. — [Mesenchymal Stem Cells: Time to Change the Name!](https://pubmed.ncbi.nlm.nih.gov/28452204/). *Stem cells translational medicine*, 2017. DOI: 10.1002/sctm.17-0051. 2. A concise review of mesenchymal stem cells for functional cartilage tissue engineering sets out the underlying problem: articular cartilage is avascular and has very limited intrinsic repair capacity, which is precisely why engineered and cell-based approaches are being pursued - and why building tissue that matches native articular cartilage in composition and mechanical function remains an unsolved engineering problem rather than a delivered clinical product. Tan AR, et al. — [Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.](https://pubmed.ncbi.nlm.nih.gov/28177194/). *Stem cells translational medicine*, 2017. DOI: 10.1002/sctm.16-0271. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. 6. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing, topical NSAIDs, oral NSAIDs and intra-articular glucocorticoid injection in knee OA. Notably it does NOT strongly recommend any biologic injectable. Kolasinski SL, et al. — [2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.](https://pubmed.ncbi.nlm.nih.gov/31908163/). *Arthritis & rheumatology (Hoboken, N.J.)*, 2020. DOI: 10.1002/art.41142. 7. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 8. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another. Yoshioka T, et al. — [The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/39097760/). *The American journal of sports medicine*, 2024. DOI: 10.1177/03635465241263073. ## What is regenerative medicine? Regenerative medicine covers treatments meant to help the body repair instead of only quieting soreness. For worn joints, that can mean a shot using blood the clinic has spun. It’s called PRP, short for platelet-rich plasma. The name doesn’t mean cartilage, the smooth cover on bone ends, will grow back. ## Does regenerative therapy work for knees? A PRP blood shot may ease some knee soreness, but results differ. Good proof doesn’t show it rebuilds the smooth cover across a worn joint. Ask what may change in walking, stairs, or sleep. Compare the price and recovery with exercise, medicine, and surgery. ## How does regenerative medicine work? For PRP, the clinic spins blood so one part holds more platelets, the small pieces that help clotting. That part enters the sore joint through a shot. It may ease irritation for a time. It doesn’t make the worn joint new. ## What can I try at home? Keep moving, but shorten or change the activity that brings on the ache. Level walking may feel better than hills, quick turns, or a long day out. Gentle strength work may help nearby muscles carry the load, provided soreness hasn’t risen later. Stop an exercise that causes a sharp change and ask for help. ## Does insurance pay for regenerative medicine? Many joint treatments are paid from your pocket. Don’t trust a spoken estimate. Ask the clinic what you’ll owe if insurance pays nothing, then ask your insurance company to confirm its share and the cost of return visits in writing before you agree. ## Where can I get regenerative medicine in Phoenix? The Peoria clinic at 13128 N. 94th Drive, Suite 205 is the nearby choice listed here. From central Surprise, use Bell Road, Loop 101, and Thunderbird Road. Call (602) 837-PAIN to check appointment details before driving. There, QC Kinetix medical providers, the clinic staff who examine joints, discuss non-surgical regenerative treatments such as a blood-based joint shot. ## What to ask at the visit Bring the names of your pills, old x-rays or scan reports, and notes on what makes the joint ache. Name the daily task you’d like to handle with less trouble. Ask about the entire price, the relief you might notice, and when you can judge the result. A website can’t tell whether the ache comes from bone, muscle, or another part of the joint. An exam can help, while sudden warning signs need care equipped for quick tests. QC Kinetix medical providers, meaning the clinic staff who examine you, can discuss regenerative treatments such as a joint shot made after your blood is drawn and spun. Book a free consultation: --- Plain help for a sore joint Simple answers for sore joints in Surprise, including daily care, urgent changes, and treatment choices. Plain help with joint soreness, home care, clinic choices, and honest limits for Surprise readers. Surprise Joint Fieldbook is operated by the owners of QC Kinetix's Phoenix-area clinics, making the Peoria referral on these pages a first-party recommendation. Copyright 2026 Surprise Joint Fieldbook. General joint-health education for Arizona readers, not individual medical advice.